O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+37.59%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$7.86B
AUM Growth
+$7.86B
(+17%)
Cap. Flow
+$167M
Cap. Flow
% of AUM
2.12%
Top 10 Holdings %
Top 10 Hldgs %
39.67%
Holding
137
New
17
Increased
32
Reduced
42
Closed
9
Top Buys
| 1 |
AGN
ALLERGAN INC
AGN
|
$186M |
| 2 |
Intuitive Surgical
ISRG
|
$115M |
| 3 |
ESRX
Express Scripts Holding Company
ESRX
|
$60.8M |
| 4 |
AbbVie
ABBV
|
$53.1M |
| 5 |
Neurocrine Biosciences
NBIX
|
$45.4M |
Top Sells
| 1 |
AET
Aetna Inc
AET
|
$83.2M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$60M |
| 3 |
ITMN
INTERMUNE INC
ITMN
|
$58.4M |
| 4 |
UnitedHealth
UNH
|
$56.5M |
| 5 |
CELG
Celgene Corp
CELG
|
$53.8M |
Sector Composition
| 1 | Healthcare | 86.06% |
| 2 | Technology | 0.09% |
| 3 | Financials | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ICPT
1
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $572M | 7.04% | 1,734,934 | – | – |
|
2
Gilead Sciences
GILD
$140B
| $377M | 4.63% | 5,314,800 +322,200 | +6% | +$22.8M |
|
3
Biogen
BIIB
$19.4B
| $324M | 3.99% | 1,060,700 -34,400 | -3% | -$10.5M |
|
4
Bristol-Myers Squibb
BMY
$96B
| $310M | 3.81% | 5,966,400 +501,400 | +9% | +$26M |
|
|
RLYP
5
DELISTED
RELYPSA INC COM
RLYP
| $296M | 3.64% | 9,941,551 +2 | +0% | +$60 |
|
6
Amgen
AMGN
$155B
| $286M | 3.51% | 2,315,900 -199,400 | -8% | -$24.6M |
|
|
AGN
7
DELISTED
ALLERGAN INC
AGN
| $282M | 3.46% | 2,270,000 +1,494,800 | +193% | +$186M |
|
|
8
AbbVie
ABBV
$372B
| $246M | 3.03% | 4,793,800 +1,032,900 | +27% | +$53.1M |
|
9
HCA Healthcare
HCA
$94.5B
| $221M | 2.72% | 4,215,000 +457,000 | +12% | +$24M |
|
10
Illumina
ILMN
$15.8B
| $202M | 2.49% | 1,360,500 -236,300 | -15% | -$35.1M |
|
|
ITMN
11
DELISTED
INTERMUNE INC
ITMN
| $199M | 2.45% | 5,952,000 -1,745,000 | -23% | -$58.4M |
|
|
CELG
12
DELISTED
Celgene Corp
CELG
| $191M | 2.35% | 1,371,400 -385,700 | -22% | -$53.8M |
|
13
Viatris
VTRS
$12.3B
| $191M | 2.35% | 3,905,500 -309,000 | -7% | -$15.1M |
|
|
MDVN
14
DELISTED
MEDIVATION, INC.
MDVN
| $175M | 2.16% | 2,724,100 -399,400 | -13% | -$25.7M |
|
15
Agilent Technologies
A
$35.7B
| $170M | 2.09% | 3,042,600 +25,000 | +0.8% | +$1.4M |
|
16
Thermo Fisher Scientific
TMO
$186B
| $168M | 2.06% | 1,393,200 -141,000 | -9% | -$17M |
|
17
Incyte
INCY
$16.5B
| $167M | 2.06% | 3,124,000 -945,000 | -23% | -$50.6M |
|
18
Perrigo
PRGO
$3.27B
| $163M | 2.01% | 1,056,800 +283,800 | +37% | +$43.9M |
|
|
19
Regeneron Pharmaceuticals
REGN
$61.5B
| $162M | 1.99% | 539,000 -199,800 | -27% | -$60M |
|
|
ESRX
20
DELISTED
Express Scripts Holding Company
ESRX
| $157M | 1.94% | 2,097,000 +810,000 | +63% | +$60.8M |
|
|
21
Intuitive Surgical
ISRG
$170B
| $147M | 1.81% | 336,300 +261,800 | +351% | +$115M |
|
22
Merck
MRK
$210B
| $145M | 1.78% | 2,547,000 | – | – |
|
|
IPXL
23
DELISTED
Impax Laboratories, Inc.
IPXL
| $141M | 1.74% | 5,345,600 +1,108,000 | +26% | +$29.3M |
|
24
Pfizer
PFE
$141B
| $118M | 1.45% | 3,661,000 +108,000 | +3% | +$3.47M |
|
25
McKesson
MCK
$85.4B
| $102M | 1.26% | 579,000 +224,000 | +63% | +$39.6M |
|